What the FDA labels say about taking them together
Cobicistat and everolimus
Cobicistat's FDA label of February 10, 2026 names everolimus in its drug interactions section; the everolimus labels PlainMeds reads (2) do not name cobicistat. The cobicistat label: “These immunosuppressant agents are metabolized by CYP3A. Therapeutic drug monitoring is recommended if coadministered.”
Check it at the source: the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.); the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation).
What does the cobicistat label say about everolimus?
Cobicistat label, drug interactionsConcomitant Drug Class/Drug Name: Immuno-suppressants: cyclosporine everolimus sirolimus tacrolimus; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↑ immuno-suppressants; Clinical Comment: These immunosuppressant agents are metabolized by CYP3A. Therapeutic drug monitoring is recommended if coadministered.
Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed
What does the everolimus label say about cobicistat?
Everolimus's label (effective June 1, 2026) and its 1 other brand-application label do not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat | Everolimus | |
|---|---|---|
| Labeled for | HIV | Breast cancer, Seizures and epilepsy, Organ transplant rejection |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $26.32 per tablet 10 mg tablet |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once